Immutep Limited (NASDAQ:IMMP) price on Friday, August 27, rose 3.88% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $3.75.
A look at the stock’s price movement, the close in the last trading session was $3.61, moving within a range at $3.59 and $3.76. The beta value (5-Year monthly) was 1.45. Turning to its 52-week performance, $7.95 and $1.22 were the 52-week high and 52-week low respectively. Overall, IMMP moved 9.33% over the past month.
3 Tiny Stocks Primed to Explode The worlds greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
Weve set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Immutep Limited’s market cap currently stands at around $243.27 million.
The average forecast suggests down to a -85.30% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue for 2021 to grow to $1.46 million, representing a -85.30% decline on that reported in the last financial year.
Revisions could be used as tool to get short term price movement insight, and for the company that in the past seven days was no upward and no downward review(s). Turning to the stock’s technical picture we see that short term indicators suggest on average that IMMP is a Hold. On the other hand, the stock is on average a 50% Buy as suggested by medium term indicators while long term indicators are putting the stock in 50% Buy category.
5 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 5 recommend IMMP as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
IMMP’s current price about 6.59% and 0.80% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 57.60, while 7-day volatility ratio is 5.28% and 5.20% in the 30-day chart. Further, Immutep Limited (IMMP) has a beta value of 0, and an average true range (ATR) of 0.17. Analysts have given the company’s stock an average 52-week price target of $8.58, forecast between a low of $7.48 and high of $10.11. Looking at the price targets, the low is -99.47% off current price level while to achieve the yearly target high, price needs to move -169.6%. Nonetheless, investors will most likely welcome a -121.33% jump to $8.30 which is the analysts’ median price.
In the market, a comparison of Immutep Limited (IMMP) and its peers suggest the former has performed considerably stronger. Data shows IMMP’s intraday price has changed 3.88% in last session and 179.85% over the past year. Comparatively, Radius Health Inc. (RDUS) has moved 2.71% on the day and only 11.78% in the past 12 months. Looking at another peer, we see that Illumina Inc. (ILMN) price has dipped -1.33% on the day. However, the stock is 32.32% off its price a year ago. Moreover, HTG Molecular Diagnostics Inc. (HTGM) is also down -3.41% in trading on the day while keeping a an uptrend of 17.48% over the past year. Elsewhere, the overall performance for the S&P 500 and Dow Jones Industrial shows that the indexes are up 0.88% and 0.69% respectively in the last trading.
If we refocus on Immutep Limited (NASDAQ:IMMP), historical trading data shows that trading volumes averaged 0.26 million over the past 10 days and 432.43K over the past 3 months. The company’s latest data on shares outstanding shows there are 64.87 million shares.
The institutional holders own 7.20% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 0.53 million on Jun 29, 2021, giving us a short ratio of 0.98. The data shows that as of Jun 29, 2021 short interest in Immutep Limited (IMMP) stood at 0.82% of shares outstanding, with shares short rising to 0.49 million registered in May 27, 2021. Current price change has pushed the stock 19.43% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the IMMP stock continues to rise going into the next quarter.
Find us at the office
Darmofal- Broderick street no. 11, 88736 Vatican City, Vatican City
Give us a ring
+90 293 316 242
Mon - Fri, 8:00-14:00